Medtronic Inc. (MDT) isn’t giving up on a new approach to treat hypertension with a device designed to sear the nerves that spur high blood pressure, even though the first rigorous trial of the method failed to help patients, company officials said. Blood pressure for those getting the procedure, called renal denervation, fell by 14 points, according to research presented today at the American College of Cardiology meeting in Washington. That’s roughly the same as the 11 point dip seen in the study in those who received a sham procedure.
Help employers find you! Check out all the jobs and post your resume.
